346 related articles for article (PubMed ID: 31357013)
1. Association between treatment duration and mortality or relapse in adult patients with Staphylococcus aureus bacteraemia: a retrospective cohort study.
Abbas M; Rossel A; de Kraker MEA; von Dach E; Marti C; Emonet S; Harbarth S; Kaiser L; Uçkay I
Clin Microbiol Infect; 2020 May; 26(5):626-631. PubMed ID: 31357013
[TBL] [Abstract][Full Text] [Related]
2. Relative efficacy of cefuroxime versus dicloxacillin as definitive antimicrobial therapy in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-score adjusted retrospective cohort study.
Rasmussen JB; Knudsen JD; Arpi M; Schønheyder HC; Benfield T; Ostergaard C
J Antimicrob Chemother; 2014 Feb; 69(2):506-14. PubMed ID: 24078468
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.
Baxi SM; Clemenzi-Allen A; Gahbauer A; Deck D; Imp B; Vittinghoff E; Chambers HF; Doernberg S
Antimicrob Agents Chemother; 2016 Sep; 60(9):5276-84. PubMed ID: 27324762
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial.
Thorlacius-Ussing L; Andersen CØ; Frimodt-Møller N; Knudsen IJD; Lundgren J; Benfield TL
Trials; 2019 May; 20(1):250. PubMed ID: 31046810
[TBL] [Abstract][Full Text] [Related]
5. Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.
Chong YP; Moon SM; Bang KM; Park HJ; Park SY; Kim MN; Park KH; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS
Antimicrob Agents Chemother; 2013 Mar; 57(3):1150-6. PubMed ID: 23254436
[TBL] [Abstract][Full Text] [Related]
6. Adherence to standards of care and mortality in the management of Staphylococcus aureus bacteraemia in Peru: A prospective cohort study.
Schwalb A; Cachay R; de la Flor A; García C; Seas C
Int J Infect Dis; 2020 Jul; 96():601-606. PubMed ID: 32505877
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case-control and cohort analysis.
Nissen JL; Skov R; Knudsen JD; Ostergaard C; Schønheyder HC; Frimodt-Møller N; Benfield T
J Antimicrob Chemother; 2013 Aug; 68(8):1894-900. PubMed ID: 23599360
[TBL] [Abstract][Full Text] [Related]
8. Staphylococcus aureus bacteraemia--Nationwide assessment of treatment adequacy and outcome.
Asgeirsson H; Kristjansson M; Kristinsson KG; Gudlaugsson O
J Infect; 2011 May; 62(5):339-46. PubMed ID: 21402101
[TBL] [Abstract][Full Text] [Related]
9. Outcome of inappropriate empirical antibiotic therapy in patients with Staphylococcus aureus bacteraemia: analytical strategy using propensity scores.
Kim SH; Park WB; Lee CS; Kang CI; Bang JW; Kim HB; Kim NJ; Kim EC; Oh MD; Choe KW
Clin Microbiol Infect; 2006 Jan; 12(1):13-21. PubMed ID: 16460541
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Cohort Study of Durations of
Kang CK; Song KH; Kim SE; Kim ES; Park WB; Park KH; Chun SH; Lee S; Cho CR; Kang SJ; Oh MD; Kim YS; Lee SH; Kwak YG; Jang HC; Kim CJ; Kim YK; Bang JH; Kiem S; Kwon KT; Jung Y; Kang YM; Jung SI; Kim HB;
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636069
[TBL] [Abstract][Full Text] [Related]
11. Comparable Effectiveness of Cefuroxime and Piperacillin-Tazobactam as Empirical Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia.
Bigseth RS; Sandholdt H; Petersen A; Østergaard C; Benfield T; Thorlacius-Ussing L
Microbiol Spectr; 2022 Jun; 10(3):e0153021. PubMed ID: 35438533
[TBL] [Abstract][Full Text] [Related]
12. Effect of statin therapy in the outcome of bloodstream infections due to Staphylococcus aureus: a prospective cohort study.
López-Cortés LE; Gálvez-Acebal J; Del Toro MD; Velasco C; de Cueto M; Caballero FJ; Muniain MA; Pascual A; Rodríguez-Baño J
PLoS One; 2013; 8(12):e82958. PubMed ID: 24376617
[TBL] [Abstract][Full Text] [Related]
13. Gender differences in the outcome of community-acquired Staphylococcus aureus bacteraemia: a historical population-based cohort study.
Smit J; López-Cortés LE; Kaasch AJ; Søgaard M; Thomsen RW; Schønheyder HC; Rodríguez-Baño J; Nielsen H
Clin Microbiol Infect; 2017 Jan; 23(1):27-32. PubMed ID: 27343816
[TBL] [Abstract][Full Text] [Related]
14. Impact of a pharmacist-driven care package on Staphylococcus aureus bacteremia management in a large community healthcare network: A propensity score-matched, quasi-experimental study.
Smith JR; Frens JJ; Snider CB; Claeys KC
Diagn Microbiol Infect Dis; 2018 Jan; 90(1):50-54. PubMed ID: 29153470
[TBL] [Abstract][Full Text] [Related]
15. The benefits and safety of oral sequential antibiotic therapy in non-complicated and complicated Staphylococcus aureus bacteremia.
Pérez-Rodríguez MT; Sousa A; Moreno-Flores A; Longueira R; Diéguez P; Suárez M; Lima O; Vasallo FJ; Álvarez-Fernández M; Crespo M
Int J Infect Dis; 2021 Jan; 102():554-560. PubMed ID: 33157291
[TBL] [Abstract][Full Text] [Related]
16. Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013.
Coombs GW; Nimmo GR; Daly DA; Le TT; Pearson JC; Tan HL; Robinson JO; Collignon PJ; McLaws ML; Turnidge JD;
Commun Dis Intell Q Rep; 2014 Dec; 38(4):E309-19. PubMed ID: 25631593
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT.
Thwaites GE; Scarborough M; Szubert A; Saramago Goncalves P; Soares M; Bostock J; Nsutebu E; Tilley R; Cunningham R; Greig J; Wyllie SA; Wilson P; Auckland C; Cairns J; Ward D; Lal P; Guleri A; Jenkins N; Sutton J; Wiselka M; Armando GR; Graham C; Chadwick PR; Barlow G; Gordon NC; Young B; Meisner S; McWhinney P; Price DA; Harvey D; Nayar D; Jeyaratnam D; Planche T; Minton J; Hudson F; Hopkins S; Williams J; Török ME; Llewelyn MJ; Edgeworth JD; Walker AS
Health Technol Assess; 2018 Oct; 22(59):1-148. PubMed ID: 30382016
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.
Holmes NE; Turnidge JD; Munckhof WJ; Robinson JO; Korman TM; O'Sullivan MV; Anderson TL; Roberts SA; Warren SJ; Gao W; Johnson PD; Howden BP
Clin Microbiol Infect; 2013 Dec; 19(12):1163-8. PubMed ID: 23441652
[TBL] [Abstract][Full Text] [Related]
19. Comparable Outcomes of Short-Course and Prolonged-Course Therapy in Selected Cases of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Pooled Cohort Study.
Thorlacius-Ussing L; Sandholdt H; Nissen J; Rasmussen J; Skov R; Frimodt-Møller N; Dahl Knudsen J; Østergaard C; Benfield T
Clin Infect Dis; 2021 Sep; 73(5):866-872. PubMed ID: 33677515
[TBL] [Abstract][Full Text] [Related]
20. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries.
Ammerlaan H; Seifert H; Harbarth S; Brun-Buisson C; Torres A; Antonelli M; Kluytmans J; Bonten M;
Clin Infect Dis; 2009 Oct; 49(7):997-1005. PubMed ID: 19719417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
